董事会宣布，于2025年12月15日，待达成承授人同意注销先前授出奖励后，公司将根据公司于2025年5 月26日采纳的2025年H股激励计划向承授人授出430,500份股份奖励(「2025年12月授出」)，以取代先前 授出奖励。 格隆汇12月15日丨心玮医疗-B(06609.HK)宣布，于2025年12月15日，其已决议注销根据2021年H股激励 计划向集团若干管理人员授出的430,500股奖励股份(「先前授出奖励」)。董事会认为，注销先前授出奖 励及重新授出新股份奖励将激励承授人为集团的成功作出最大努力并奖励其持续努力，以及提高效率并 降低公司管理其现有激励计划的成本。 ...

Group 1 - The core point of the announcement is that Sichuan Kelun Pharmaceutical Co., Ltd. plans to implement a share incentive plan for its subsidiary, Kelun Biotech, to attract and retain core talent and align interests among shareholders, the company, and key personnel [1][10]. Group 2 - The incentive plan will grant restricted share units, with a maximum of 3,500,000 H-shares to be issued, representing approximately 1.5% of the total shares of Kelun Biotech on the date of approval [2]. - The plan aims to establish a long-term incentive mechanism to support the strategic and operational goals of Kelun Biotech [3]. - The plan will be effective for ten years from the adoption date, with no new share awards to be granted after the expiration [3]. Group 3 - Eligible participants include directors and employees of Kelun Biotech and its subsidiaries, with selection based on performance, tenure, and contributions [4]. - The purchase price for the shares is set at RMB 1.00 per share, with a vesting period of four years, and performance targets must be met for the shares to vest [6]. - The management of the incentive plan will be overseen by the board of directors or authorized representatives of Kelun Biotech [7]. Group 4 - The incentive plan has been approved by the board of directors of Kelun Biotech but requires shareholder approval and listing approval from the Hong Kong Stock Exchange [9]. - The implementation of the plan is expected to enhance the core competitiveness and sustainable development of Kelun Biotech without adversely affecting the financial status or operational results of the parent company [10].

Core Viewpoint - Kolun Pharmaceutical (002422.SZ) announced the implementation of a long-term incentive plan for its subsidiary, Sichuan Kolun Botai Biopharmaceutical Co., Ltd. (6990.HK), aimed at attracting and retaining key talent to drive business development and align interests among shareholders, the company, and core personnel [1] Group 1 - The incentive plan will grant restricted stock units, with shares sourced from new H-shares issued by Kolun Botai, existing treasury shares (if any), and shares purchased in the open market by a trustee [1] - The maximum number of shares to be granted under the incentive plan will not exceed 3,500,000 H-shares, which is approximately 1.5% of the total shares of Kolun Botai as of the date of the shareholders' meeting approving the plan [1] - The issuance of new H-shares under the plan will not significantly alter the company's ownership stake in Kolun Botai, which will remain a controlled subsidiary [1]

2025年股份激励计划旨在为公司建立并完善长期激励机制，吸引并留住参与者以推动集团业务发展及成 功，有效协调股东、公司及参与者的利益，促进共同关注公司的长期发展，并推动持续实现公司战略及 运营目标。 智通财经APP讯，科伦博泰生物-B(06990)发布公告，于2025年12月11日，董事会决议批准建议采纳2025 年股份激励计划。根据中国相关法律法规，2025年股份激励计划的采纳须经股东于公司股东会上审议及 批准。 ...

2025年股份激励计划旨在为公司建立并完善长期激励机制，吸引并留住参与者以推动集团业务发展及成 功，有效协调股东、公司及参与者的利益，促进共同关注公司的长期发展，并推动持续实现公司战略及 运营目标。 科伦博泰生物-B(06990)发布公告，于2025年12月11日，董事会决议批准建议采纳2025年股份激励计 划。根据中国相关法律法规，2025年股份激励计划的采纳须经股东于公司股东会上审议及批准。 ...

市场普遍关注此举将如何影响这家餐饮企业未来的经营表现与发展战略。在计划公布后的首个交易日，即11月26日，小菜园股价报收于9.68港元，当日下跌 3.01%。 另据小菜园此前公布的业绩报告，其业绩增速已出现明显放缓迹象。财报显示，小菜园营收从2023年的41.58%降至2024年的14.52%。到了2025年上半年， 营收增速进一步下滑至6.52%。 该计划的激励对象范围广泛，涵盖了公司及其成员企业的联合创始人、董事、高级管理人员、员工，甚至还包括了外部顾问及业务合作伙伴等。计划管理人 会根据相关人员对集团成长的贡献、所具备的技能及其服务保留的重要性来确定最终的激励名单。 值得注意的是，该激励计划为获益设置了明确的归属条件与锁定期。股份权益需要满足特定的期限与条件后才能归属，可以分期或一次性归属。同时，计划 明确规定，自公司上市日起的18个月内，参与者不得出售所获股份。在此之后的减持也将分阶段进行，并设有相应的比例限制。 近日，港股上市公司小菜园国际控股有限公司（0999.HK，以下简称"小菜园"）宣布董事会启动了一项股份激励计划，旨在完善公司的治理结构，建立并健 全中长期激励机制，以此调动公司管理人员、技术 ...

Core Viewpoint - The company has announced the adoption of a share incentive plan to reward and motivate individuals contributing to its growth and development, effective November 20, 2025 [1] Group 1 - The board of directors has approved the share incentive plan as part of the company's strategy to incentivize key personnel [1] - The chairman, Wang Shugang, has been authorized to manage the incentive plan and handle all related matters [1]

Core Viewpoint - The company has adopted a share incentive plan to reward and motivate individuals contributing to its growth and development, effective from November 20, 2025 [1] Group 1 - The board has resolved to implement a share incentive plan (301122) [1] - The incentive shares will primarily be in the form of options and restricted share units [1] - The plan manager has the discretion to issue other forms of incentive shares based on the company's specific circumstances [1]

Group 1 - The company, 创胜集团-B (06628), announced the grant of 200,000 reward shares to one reward grantee under its share incentive plan [1] - Additionally, the company granted 800,000 stock options to two option grantees under the same share incentive plan [1]

Core Viewpoint - Singularity Guofeng (01280) announced the issuance of new shares amounting to 25.2006 million shares as part of its share incentive plan, which will be granted to the trustee of the issuer on October 30, 2025 [1] Group 1 - The company is implementing a share incentive plan to motivate and retain key personnel [1] - The total number of new shares issued is 25.2006 million [1]